<DOC>
	<DOCNO>NCT01523080</DOCNO>
	<brief_summary>The study compare single-dose oral bioavailability acetaminophen 650 mg extend release geltabs ( contain acetaminophen 650 mg ) OHM Laboratories Inc. ( subsidiary Ranbaxy Pharmaceuticals Inc. , USA ) Tylenol 8 hour extend release gel tab ( contain acetaminophen 650 mg ) McNeil Consumer &amp; Speciality Pharmaceuticals , U.S.A healthy , adult , male human subject fast condition .</brief_summary>
	<brief_title>A Relative Bioavailability Study Acetaminophen Extended Release Gel Tabs 650 mg Under Fasting Condition</brief_title>
	<detailed_description>The study conduct open label , balance , randomise , two-treatment , two-period , two-sequence , single dose , crossover bioavailability study compare acetaminophen 650 mg extend release gel tab ( contain acetaminophen 650 mg ) OHM Laboratories Inc. ( subsidiary Ranbaxy ) Tylenol 8 hour extend release gel tab ( contain acetaminophen 650 mg ) McNeil Consumer &amp; Speciality Pharmaceuticals healthy , adult , human , male subject fast condition . The treatment assign study subject accord SAS generate randomization schedule . Each subject receive single oral dose either Test Reference product period 240ml water ambient temperature overnight fast least 10 hour supervision train study personnel . During course study , safety parameter inclusive vital sign , clinical examination , medical history clinical laboratory safety test ( hematology , biochemical , serology parameter urine analysis ) base line assess . Laboratory parameter hematology biochemistry repeat end study .</detailed_description>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Were age range 1845 year . Were neither overweight underweight height per Life Insurance Corporation India height/weight chart nonmedical case . Had voluntarily give write informed consent participate study . Were normal health determine medical history physical examination subject perform within 21 day prior commencement study . History hypersensitivity Acetaminophen components formulation . History skin rash , thrombocytopenia , urticaria angioedema Any evidence organ dysfunction clinically significant deviation normal , physical clinical determination . Presence disease marker HIV 1 2 , Hepatitis B C viruses syphilis infection . Presence value significantly different normal reference range and/or judge clinically significant haemoglobin , total white blood cell count , differential WBC count platelet count . Positive urinary screen test drug abuse ( opiates cannabinoids ) Presence value , significantly different normal reference range and/or judge clinically significant serum creatinine , blood urea nitrogen , serum aspartate aminotransferase ( AST ) , serum alanine aminotransferase ( ALT ) , serum alkaline phosphatase , serum bilirubin , plasma glucose serum cholesterol . Clinically abnormal chemical microscopic examination urine define presence RBC , WBC ( &gt; 4/HPF ) , epithelial cell ( &gt; 4/HPF ) , glucose ( positive ) protein ( positive ) . Clinically abnormal ECG Chest Xray . History serious gastrointestinal , hepatic , renal , cardiovascular , pulmonary , neurological haematological disease , diabetes glaucoma ( rise pressure inside eye lead blurring loss vision ) History psychiatric illness , might impair ability provide write informed consent . Regular smoker smoke 10 cigarette daily difficulty abstain smoke duration study period . History drug dependence excessive alcohol intake habitual basis 2 unit alcoholic beverage per day ( 1 unit equivalent half pint beer 1 glass wine 1 measure spirit ) difficulty abstain duration study period . Use enzyme modifying drug within 30 day prior Day 1 study . Participation clinical trial within 12 week precede Day 1 study . Subjects , completion study , would donate and/or lose 350 mL blood past 3 month .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>